The Outcome of Ibrutinib-Based Regimens in Relapsed/refractory Central Nervous System Lymphoma and the Potential Impact of Genomic Variants.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE（2023）
Key words
ibrutinib,tumor mutation burden,central nervous system lymphoma,relapsed/refractory,genomic variants
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined